PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 26, 2026Molecules0 citationsOpen Access

Establishment of Nucleic Acid Amplification Technology for the Detection of Mycoplasma in Biological Products

View Full Paper
YGYing GuoXQXi QinJZJing Zhang

Key Points

  • The aim is to establish a fast and sensitive method for detecting Mycoplasma in biological products using nucleic acid amplification technology.
  • Developed a Nucleic Acid Amplification Technology (NAT) method for detecting Mycoplasma.
  • Utilized multiplex quantitative PCR (qPCR) with fluorescent probes and universal primers based on the 16S rRNA gene.
  • Validated detection performance and sample applicability according to ICH and European Pharmacopoeia guidelines.
  • Achieved a limit of detection (LOD) of 10 CFU/mL for Mycoplasma contamination.
  • Tested all biological product samples spiked with 10 CFU/mL of Mycoplasma, confirming positive results.
  • Met predefined requirements for sensitivity, specificity, and robustness of the NAT-based detection method.

Abstract

Currently, the most commonly used methods for detecting Mycoplasma are the culture method and the indicator cell culture method. However, both approaches exhibit low sensitivity and are incapable of detecting low-concentration contamination. In addition, the detection period may extend up to 28 days, which is unsuitable for rapid screening and may delay timely contamination control measures. To address these limitations, a Mycoplasma detection method based on nucleic acid amplification technology (NAT) was developed following a comparative analysis of gene sequences from various Mycoplasma species. The method was validated with respect to its detection performance and its applicability to biological product samples. DNA was extracted from Mycoplasma-contaminated samples using a magnetic bead-based nucleic acid extraction method. Universal primers were designed based on the highly conserved 16S rRNA gene sequence of Mycoplasma, and amplification was performed using multiplex quantitative PCR (qPCR) with fluorescent probes. The limit of detection (LOD) was established based on statistics of 24 replicates. Method specificity and robustness were evaluated according to the guidelines set by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH Q2), while sample applicability was assessed in accordance with the European Pharmacopoeia (EP) . The NAT-based Mycoplasma detection method enabled rapid, qualitative identification of Mycoplasma contamination. The validated LOD was 10 CFU/mL, and the method met predefined requirements for sensitivity, specificity, and robustness. To assess applicability, real biological product samples, including monoclonal antibodies, antibody fusion proteins, bispecific antibodies, and trispecific antibodies, were spiked with 10 CFU/mL of standard Mycoplasma strains. All spiked samples tested positive. These findings confirm that the NAT-based Mycoplasma detection method is suitable for process control and product release testing in the production of biological products.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Guo et al. (2026) studied this question.

synapsesocial.com/papers/6a153b00b5d9c58d83e8d2ebhttps://doi.org/10.3390/molecules31111794
Ask AI
Helpful
Bookmark
Share
View Full Paper